Democratic Drug Pricing Push: Starting And Ending With Insulin?
Executive Summary
When the Democratic party regained control of the US House of Representatives in 2019, their push to enact comprehensive drug pricing legislation began with a hearing on insulin. After four years, it might be ending with insulin as the sole focus after all.
You may also be interested in...
Insulin Prices, Cancer Treatment Innovation Pushed In State Of The Union As Biden Faces Divided Congress
Expanded federal research efforts around cancer treatment was one of a handful of bipartisan goals that President Biden highlighted in his State of the Union address.
Drug Price Increases Accelerate: ‘Political Opportunism’ In A Return To Business As Usual?
Advocates for drug pricing reform don’t have much in the way of price increases to complain about at the moment – but they argue that the price hikes they are seeing suggest a growing confidence among manufacturers that the threat of drug pricing reform is subsiding.
Civica Takes On The Challenge Of Insulin Affordability
The non-profit organization plans to make biosimilar versions of Lantus, Humalog and Novolog and sell them for no more than $30/vial.